2-methoxyestradiol-3-17-o-o-bis(sulfamate) and sulfamic-acid

2-methoxyestradiol-3-17-o-o-bis(sulfamate) has been researched along with sulfamic-acid* in 4 studies

Reviews

1 review(s) available for 2-methoxyestradiol-3-17-o-o-bis(sulfamate) and sulfamic-acid

ArticleYear
Sulfamates in drug design and discovery: Pre-clinical and clinical investigations.
    European journal of medicinal chemistry, 2019, Oct-01, Volume: 179

    In the present article, we reviewed the sulfamate-containing compounds reported as bioactive molecules. The possible molecular targets of sulfamate derivatives include steroid sulfatase enzyme, carbonic anhydrases, acyl transferase, and others. Sulfamate derivatives can help treat hormone-dependent tumors including breast, prostate, and endometrial cancers, Binge eating disorder, migraine, glaucoma, weight loss, and epilepsy. Sulfamate derivatives can act also as calcium sensing receptor agonists and can aid in osteoporosis. Furthermore, acyl sulfamate derivatives can act as antibacterial agents against Gram-positive bacteria. A recent study revealed a new side effect of topiramate, a sulfamate-containing compound, which is sialolithiasis. The structural and biological characteristics of the reviewed compounds are presented in detail.

    Topics: Anti-Bacterial Agents; Drug Discovery; Gram-Positive Bacteria; Microbial Sensitivity Tests; Molecular Structure; Sulfonic Acids

2019

Other Studies

3 other study(ies) available for 2-methoxyestradiol-3-17-o-o-bis(sulfamate) and sulfamic-acid

ArticleYear
2-Methoxyestradiol-3,17-O,O-bis-sulfamate inhibits store-operated Ca
    Biochimica et biophysica acta. Molecular cell research, 2023, Volume: 1870, Issue:6

    Topics: 2-Methoxyestradiol; Animals; Encephalomyelitis, Autoimmune, Experimental; Pharmaceutical Preparations; Rats; Rats, Inbred Lew; T-Lymphocytes

2023
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
    Journal of medicinal chemistry, 2015, Oct-08, Volume: 58, Issue:19

    In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and women's health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future.

    Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosis; Estrone; Female; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Steryl-Sulfatase; Sulfonic Acids; Tubulin Modulators

2015
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.
    Journal of medicinal chemistry, 2006, Dec-28, Volume: 49, Issue:26

    The anticancer activities and SARs of estradiol-17-O-sulfamates and estradiol 3,17-O,O-bis-sulfamates (E2bisMATEs) as steroid sulfatase (STS) inhibitors and antiproliferative agents are discussed. Estradiol 3,17-O,O-bis-sulfamates 20 and 21, in contrast to the 17-O-monosulfamate 11, proved to be excellent STS inhibitors. 2-Substituted E2bisMATEs 21 and 23 additionally exhibited potent antiproliferative activity with mean graph midpoint values of 18-87 nM in the NCI 60-cell-line panel. 21 Exhibited antiangiogenic in vitro and in vivo activity in an early-stage Lewis lung model, and 23 dosed p.o. caused marked growth inhibition in a nude mouse xenograft tumor model. Modeling studies suggest that the E2bisMATEs and 2-MeOE2 share a common mode of binding to tubulin, though COMPARE analysis of activity profiles was negative. 21 was cocrystallized with carbonic anhydrase II, and X-ray crystallography revealed unexpected coordination of the 17-O-sulfamate of 21 to the active site zinc and a probable additional lower affinity binding site. 2-Substituted E2bisMATEs are attractive candidates for further development as multitargeted anticancer agents.

    Topics: Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Carbonic Anhydrase II; Carcinoma, Lewis Lung; Cell Proliferation; Crystallography, X-Ray; Estradiol; Female; Humans; Mice; Mice, Nude; Models, Molecular; Neovascularization, Pathologic; Steryl-Sulfatase; Structure-Activity Relationship; Sulfonic Acids; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zinc

2006